To the Editor,
Approximately 25% of the asthmatic children suffer from uncontrolled asthma despite regular use of inhaled corticosteroids (ICS). Variation within the 17q21 locus is the strongest genetic determinant for childhood‐onset asthma. Recently, the influence of this locus on treatment outcomes has been shown in several studies. The Pharmacogenomics in Childhood Asthma (PiCA) consortium is a multiethnic consortium that brings together data from ≥14 000 asthmatic children/young adults from 12 different countries to study the pharmacogenomics of uncontrolled asthma despite treatment. In 14 PiCA populations (with over 4000 asthmatic patients), we studied the association between variation in the 17q21 locus, and asthma exacerbations despite ICS use. We specifically focused on rs7216389, a single nucleotide polymorphism (SNP) in the 17q21 locus strongly associated with childhood asthma and initially identified by Moffatt et al. [...],
Erasmus MC: University Medical Center Rotterdam

Farzan, Niloufar, Vijverberg, S., Hernandez-Pacheco, N., Bel, E. H., Berce, Vojko, Bønnelykke, K., … Maitland-van der Zee, A.-H. (2018). 17q21 variant increases the risk of exacerbations in asthmatic children despite inhaled corticosteroids use. Allergy. doi:10.1111/all.13499